The Intensive Care Platform Trial (INCEPT) is an international adaptive platform trial aimed at improving care for adults acutely admitted to the intensive care unit.
Unique patients randomised
INCEPT-Albumin enrolments
INCEPT-Tromboprophylaxis enrolments
Active sites
Active countries
We are working on ensuring continuous and lasting funding of INCEPT as a whole along with funding of specific domains.
The INCEPT research programme is funded by the Novo Nordisk Foundation and Sygeforsikringen “danmark”, with additional support by Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond, Dagmar Marshalls fond, and Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat.
The INCEPT-Albumin domain is partially funded by Danmarks Frie Forskningsfond.
The INCEPT-Thromboprophylaxis domain is additionally funded by the Netherlands Thrombosis Foundation.
The upcoming INCEPT-Bicarbonate domain has received funding from Danmarks Frie Forskningsfond and Sundhedsdonationer fra Sygeforsikringen “danmark”.
The upcoming INCEPT-AFIB domain has received support from Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond.
The upcoming INCEPT-Glucose domain is funded by the Novo Nordisk Foundation, with additional support by Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond.